WT RAS Signalling is an Essential Therapeutic Target In RAS-Mutated Cancers

Time: 12:30 pm
day: Day One Track B


  • RAS isoforms differentially activate RAF/MEK/ERK and PI3K/AKT effector pathways
  • Non-mutated (wild type) RAS family members activate RAS effectors that are activated poorly by mutated RAS
  • Combined inhibition of mutated RAS and WT RAS signalling synergistically kills RAS-mutated cancers